Citations

Clear

6273 citation(s) found for "To, Andrew".

Patient-reported outcome trajectories the first 24 months after surgery for cervical spondylotic myelopathy: a Quality Outcomes Database study
Zeitouni, Daniel , Johnson, Sarah E. , Bisson, Erica F. , Mummaneni, Praveen V., Haid, Regis W., Chan, Andrew K. , Chou, Dean , Wang, Michael Y. , Knightly, John J. , Meyer, Scott A., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S. , Fu, Kai-Ming, Shaffrey, Mark E., Foley, Kevin T. , Upadhyaya, Cheerag D., Potts, Eric A. , Turner, Jay D. , Uribe, Juan S. , Tumialán, Luis M. , Coric, Domagoj , Bydon, Mohamad , Asher, Anthony L. , Ibrahim, Sufyan , Mummaneni, Praveen V. , Shaffrey, Christopher I. , Fu, Kai-Ming, Park, Paul , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | January 10, 2025 | Volume: 42 | Issue: 4 | Pages: 500-508

10.3171/2024.9.spine24351 | PMID 39793008 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) shows varying levels of improvement after surgical treatment. While some patients improve soon after surgery, others may take months to years to show any signs of improvement. The goal of this study was to evaluate postoperative improvement, patient-reported outcomes, and patient satisfaction up to 2 years after surgical treatment for CSM, which will help optimize the current treatment strategies and effectively manage patient expectations. METHODS This was a retrospective study of prospectively collected data using the Quality Outcomes Database. The primary outcomes of interest were achievement of the minimal clinically important difference (MCID) for the numeric rating scale for neck and arm pain, modified Japanese Orthopaedic Association, Neck Disability Index, and EQ-5D scores and postoperative satisfaction (North American Spine Society scale). Early and sustained improvement was defined as MCID achievement in at least one patient-reported outcome measure (PROM) at the 3-, 12-, and 24-month follow-ups. Transient improvement was defined as MCID achievement only at the 3-month and/or 12-month follow-up but not at the 24-month follow-up. Late improvement was defined as MCID achievement in at least one PROM only at the 24-month follow-up. RESULTS There were 630 patients included in the comparative analysis. A total of 463 (73.5%) patients achieved early and sustained improvement, 105 (16.7%) patients experienced transient improvement with subsequent decline, 25 (4.0%) patients reported late improvement, and 37 (5.9%) patients did not report any clinically meaningful improvement after surgery. Patients with an anterior approach were more likely to be in the early and sustained improvement group. African American patients (OR 2.98, 95% CI 1.14–7.76; p = 0.03) were more likely to report late improvement when compared with White patients. The overall satisfaction rate at the 24-month follow-up was 87.8%. CONCLUSIONS These findings indicate that 73.5% of patients achieve early and sustained improvement, and 87.8% of patients are satisfied with surgery 24 months postoperatively.
Preclinical and Toxicology Assessment of ISFP10, an Inhibitor of Fungal Phosphoglucomutase (PGM)
Pellegrino, Madeline R., Bindzus, Marc, Ayyalasomayajula, Savita, Yi, Eunhee S. , Kottom, Theodore J. , Ayyalasomayajula, Savita, Limper, Andrew H.

Mayo Clinic

No container title available | January 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.07.631740 | PMID 39829820 Get It

ABSTRACT Background and Objective Previously, the novel small molecule ISFP10 has been shown to inhibit fungal phosphoglucomutase (PGM) activity in Aspergillus fumigatus and Pneumocystis spp. With 50-fold selectivity over the human PGM molecule due to the presence of a unique yet conserved cysteine residue present in a number pathogenic fungal PGMs, use of this compound may provide a novel broad-spectrum approach to treating fungal infections. Accordingly, we sought to determine the tolerability in test animals receiving this compound, as well as the potential antifungal activity of ISFP10 on cultures of the common fungal pathogens Candida albicans and Candida glabrata . Methods C57BL6 mice received once daily intraperitoneal (IP) injections of 100 mL of vehicle control (DMSO) or ISFP10 at a concentration of 10 mg/kg. Body weights were recorded daily for 7 days of treatment. On the final day, mice were weighed and euthanized. Postmortem blood collection was conducted via cardiac puncture and distributed to EDTA and lithium heparin tubes for complete blood count (CBC) and comprehensive blood chemistry panels, respectively. Liver, kidney, and lung tissue were also harvested and placed in 10% formalin for H&E staining and blinded histopathologic scoring. Lung samples were further analyzed for proinflammatory cytokines using enzyme-linked immunosorbent assays (ELISA) and quantitative PCR (qPCR). Furthermore, ISPF10 was tested for antifungal activity via 8-hour growth curve analysis in a concentration-dependent fashion against Candida albicans and Candida glabrata . Results There was no significant difference in the daily or final body weights of the mice receiving 10 mg/kg of ISFP10 compared to those of the vehicle control group. Extracellular matrix (ECM) transcripts for IL-6 and TNFα were statistically similar via qPCR. ELISA results of proinflammatory cytokines for IL-6 was not significant whereas TNFα levels in lung tissue from the ISFP10 treatment group were significantly reduced, indicating a potential anti-inflammatory effect of ISFP10 at this dosage. Overall, blood chemistry and CBC analysis revealed no overall significant differences between the two groups, except for increased neutrophil counts and decreased potassium levels in samples collected from ISFP10 treated animals compared to the vehicle control group. These laboratory abnormalities were not of clinical significance to the test animals. Blinded histopathological examination revealed no abnormalities or evidence of critical organ toxicity from all groups. Inhibition of C. albicans and C. glabrata culture growth by ISFP10 was concentration-dependent in YPD liquid media containing the ISFP10 compared to vehicle control. Conclusions Our preliminary testing of ISFP10 revealed no inherent safety or toxicology concerns within the observed parameters. These data further support significant culture suppressive activity against C. albicans and C. glabrata . Taken together, these observations of ISFP10 further indicate that targeting PGM might be a novel and viable therapeutic strategy for serious fungal infections. Key points An inhibitor specific to fungal PGM enzymes, termed ISFP10, was generally well tolerated when administered via intraperitoneal (IP) injection in mice. ISFP10 displays antifungal activity in a concentration-dependent manner against C. albicans and C. glabrata .
Discovery of Genes Underlying Cognitive Resilience in Individuals Predisposed to Alzheimer's Disease Risk
Tsai, Wei, McNiff, Caitlin E., Reddy, Joseph S. , Wang, Xue , Quicksall, Zachary , Allen, Mariet , Ren, Yingxue , Petersen, Ronald C. , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Nho, Kwangsik T. , Dunn, Amy R. , Heckman, Michael G. , Zhao, Na , Kantarci, Kejal , Mielke, Michelle M. , Kaczorowski, Catherine Cook , Carrasquillo, Minerva M. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.084683 Get It

AbstractBackgroundTwo main risk factors of Alzheimer’s disease (AD) are aging and APOE‐ε4. However, some individuals remain cognitively normal despite having these risk factors. They are considered “cognitively resilient”. This study aimed to identify molecular factors that confer cognitive resilience in APOE‐ε4 carriers ≥ 80 years of age and may serve as biomarkers.MethodWe applied weighted gene co‐expression network analysis (WGCNA) to generate consensus co‐expression networks from blood of participants in two antemortem cohorts, the Mayo Clinic Study of Aging (MCSA, n=105), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI, n=91), using RNA‐sequencing and microarray data, respectively. We associated these networks with resilience (resilient vs non‐resilient), cognitive endophenotypes and hippocampal volume. Preservation between consensus networks from blood and those derived from postmortem brain tissues of AD and control donors from AMP‐AD (n=1174) was evaluated. We validated the human findings in four AD mouse models. Finally, machine learning models were utilized to discriminate cases (AD+mild cognitive impairment (MCI)) from controls in MCSA, ADNI and ANMerge antemortem cohorts.ResultFour consensus networks were significantly correlated with a memory phenotype (logical memory delayed recall=LMDR) and hippocampal volume in both MCSA and ADNI. Among these, blood expression module M3 was most preserved with the brain transcriptome. M3 was enriched with NDUF hub genes that are involved in the mitochondrial respiratory chain. Expression levels of M3 and many blood NDUFs had significant associations with better LMDR and hippocampal volume. In brain, NDUFs were upregulated in controls compared to AD, and their expression levels were associated with better global cognition and decreased AD neuropathology. Many NDUFs were significantly downregulated in the hippocampus or cortex of AD mice compared to wild‐types. Lastly, models that included blood NDUFs improved diagnostic accuracy of AD+MCI compared to models that only included demographic and risk variables (age, sex, APOE‐ε4) in MCSA, ADNI and ANMerge. In MCSA and ADNI, adding NDUFs’ expression to models that included established blood biomarkers (Aβ42/40, ptau181, NFL) further improved diagnostic accuracy.ConclusionOur results suggest that mitochondrial NDUFs are centrally‐linked peripheral molecular signatures that may be resilience factors against AD and serve as both therapeutic targets and novel diagnostic biomarkers.
Blood‐based gene and co‐expression network levels are associated with AD/MCI diagnosis and cognitive phenotypes
Chen, Xuan , Reddy, Joseph S. , Quicksall, Zachary , Nguyen, Thuy , Reyes, Denise A., Graff‐Radford, Jonathan, Lowe, Val J. , Petersen, Ronald C., Nho, Kwangsik, Allen, Mariet , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Wang, Xue, Graff‐Radford, Jonathan , Jack, Clifford R. , Knopman, David S. , Petersen, Ronald C. , Kantarci, Kejal , Carrasquillo, Minerva M. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.086187 Get It

AbstractBackgroundAlzheimer’s disease (AD) patients have decline in cognitive domains including memory, language, visuospatial, and/or executive function and brain pathology including amyloid‐β and tau deposition, neurodegeneration, and frequent vascular co‐pathologies detectable by neuroimaging and/or cerebrospinal fluid biomarkers. However, molecular disease mechanisms are complex and heterogeneous. It is necessary to develop cost‐effective blood‐based biomarkers reflecting brain molecular perturbations in AD. We identified blood‐based gene and co‐expression network level changes associated with AD/mild cognitive impairment (MCI) diagnosis and AD‐related phenotypes.MethodWe performed differential gene expression and weighted gene co‐expression network analysis, followed by meta‐analysis, using blood transcriptome data of 391 participants from the Mayo Clinic Study of Aging and 654 participants from the Alzheimer's Disease Neuroimaging Initiative. The neuroimaging phenotypes include microhemorrhages, infarcts, amyloid burden, hippocampal volume, and white matter hyperintensities. The cognitive phenotypes include standardized cognitive subtest scores and composite scores for memory, language, visuospatial, and executive function.ResultFive out of 18 modules(M) are significantly associated with diagnosis or cognition (FDR‐adjusted p<0.05). M1 and M15 both positively associates with memory, M1 positively associated with language and M15 with visuospatial function. M1 and M15 are enriched in differentially expressed genes (DEGs) associated with language and executive function, respectively. M2 negatively associates with logical memory delayed recall scores(LMDR), memory, executive, and language functions and is enriched in DEGs for these phenotypes. M8 negatively associates with memory, language and executive functions and is enriched in DEGs for memory and language. M12 positively associates with LMDR. M1 and M15 are down‐regulated while M2 and M8 are up‐regulated in AD/MCI patients. Cell‐type enrichment analysis showed M2 is enriched in monocytes and neutrophils; M8 in monocytes; M15 in B cells (FDR <0.05). Gene ontology terms enriched in these modules indicated broad consistency with their cell types.ConclusionWe identified five modules significantly associated with AD/MCI or cognitive phenotypes using blood transcriptome data. These findings nominate blood transcriptome changes and their enriched biological processes as potential pathomechanisms in cognitive decline and AD/MCI development. We aim to investigate these blood transcripts as potential biomarkers for AD or AD‐related phenotypes and therapeutic targets through additional replication and experimental validation studies.
Pursuing dementia detection for better prevalence estimation with artificial intelligence and traditional modelling techniques in electronic health data
Liu, Ming , Rocca, Walter A. , Lu, Alicia , Siostrom, Kristy, Roberts, Helene E., Kennedy, John Clark, Collyer, Taya Annabelle , Beare, Richard , Andrew, Nadine E. , Ilomäki, Jenni , Bell, J. Simon , Sauver, Jennifer L. St. , Thrift, Amanda G. , Ung, David , Moran, Chris , Roberts, Helene, Le, Elizabeth , Kennedy, John Clark, Srikanth, Velandai

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.090057 Get It

AbstractBackgroundPopulation dementia prevalence is traditionally estimated using cohort studies, surveys, routinely‐collected administrative data, and registries. Hospital Electronic Health Records (EHRs) are comprised of rich structured and unstructured (text) clinical data that are underutilised for this purpose.We aimed to develop a suite of algorithms using routinely‐collected EHR data to reliably identify cases of dementia, as a key step towards incorporating such data in prevalence estimation. Towards this, we developed a novel predictive framework integrating data‐science and biostatistical methods.MethodTraining data were sourced via the National Centre for Healthy Ageing (NCHA) Data Platform, a linked, curated, EHR‐derived data warehouse. Individuals within the platform catchment aged >60 years with confirmed dementia were identified through hospital specialist dementia clinics. A comparison group of individuals aged >60years with EHR records without dementia was recruited from the community.A panel of clinical experts (Neurology, Geriatric Medicine) informed variable and concept selection and guided data cleaning efforts within both streams. Algorithms were developed via two work‐streams; a traditional biostatistical approach to fit logistic regression models using structured data elements, and a data science stream used Natural Language Processing (NLP) to fit models to the unstructured (text) parts of the EHR, for the same individuals.ResultOf 568 individuals (362 with dementia), 434 had clinical notes available. In the data science stream using unstructured data, among a range of NLP derived models, the Random Forest classifier performed best in assigning dementia status, with Area Under the Curve (AUC) 0.95, specificity 90.2% and sensitivity 88.4%. In the biostatistics stream, 15 structured variables were included in the final model, covering demographics, health service attendance, medications, and ICD‐10 Codes, with AUC 0.94, specificity 85.9% and sensitivity 85.6%.ConclusionArtificial intelligence techniques applied to unstructured electronic health data and guided by human clinical expertise may be powerful tools in capturing the presence of dementia, at least comparable to traditional techniques using structured data, and conferring practical and scientific advantages for dementia prevalence estimation. Future validation is required in less crisply delineated real‐world settings.
Amyloidosis and Heart Transplantation in a New Era
Lyle, Melissa , Wiedmeier-Nutor, Erin J, Lindpere, Vanda , Klanderman, Molly , Nativi-Nicolau, José , Leoni, Juan , Goswami, Rohan , Yip, Daniel , Patel, Parag C. , Sher, Taimur , Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Boilson, Barry A. , Kushwaha, Sudhir S. , Clavell, Alfredo L. , Steidley, D. Eric , Hardaway, Brian , Scott, Robert L. , LeMond, Lisa , Grogan, Martha, Rosenthal, Julie , Lyle, Melissa A , Farina, Juan Maria M, Wiedmeier-Nutor, Erin, Lindpere, Vanda , Nativi-Nicolau, Jose N, Leoni Moreno, Juan Carlos, Goswami, Rohan M , Rosenbaum, Andrew N , Steidley, David E, Hardaway, Brian W, Rosenthal, Julie L , AbouEzzeddine, Omar F , Farina, Juan M. , Leoni, Juan Carlos , Fonseca, Rafaël , Gertz, Morie A. , Dispenzieri, Angela , Grogan, Martha

Mayo Clinic

Clinical Transplantation | January 8, 2025 | Volume: 39 | Issue: 1 | Pages: No page available

10.1111/ctr.70070 | PMID 39775986 Get It

AbstractBackgroundThe prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.ObjectivesWe sought to describe survival post heart transplantation (HT) in amyloid compared with non‐amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.MethodsThis is a retrospective review of end‐stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020. Wait time was compared in the new versus old OPTN allocation era starting December 18, 2018 by Wilcoxon rank sum test. All‐cause mortality for those with and without CA was compared using Kaplan–Meier estimates with log rank analysis, censoring December 16, 2022.ResultsFifty‐five patients with CA underwent HT between 2007 and 2020, 8 light chain amyloidosis (AL) (14.5%), 28 hereditary transthyretin (ATTRv) (50.9%), 17 wildtype transthyretin (ATTRwt) (30.9%), and 2 hereditary apolipoprotein A1 (AApoA1) amyloidosis patients (3.6%). No significant difference in overall survival post‐transplant was seen in amyloid compared with non‐amyloid (p = 0.816). Median time to HT was shorter in the new system, 45 days (IQR 24, 78) versus 174 days (IQR 76.5, 483.5), p = 0.006. There was a decline in MOT in hereditary amyloidosis over time with the concomitant rise in disease‐targeted therapies.ConclusionsHT survival in CA patients was similar to non‐amyloid patients. The new allocation system benefits this cohort with shorter wait times. There is less MOT in hereditary amyloidosis with increased utilization of disease‐targeted therapy.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias , Onozawa, Masahiro , Thomson, Kirsty , Nagler, Arnon , Wei, Andrew H. , Marcucci, Guido , Chen, Caroline , Hasabou, Nahla, Rosales, Matt, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Mendizabal, Adam , Horowitz, Mary M. , Chen, Yi‐Bin , Papadopoulos, Esperanza , Perl, Alexander E , Ustun, Celalettin , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Muffly, Lori , Kim, Hee-Je , Stelljes, Matthias , Najima, Yuho , Wei, Andrew H , Hill, Jason , Chen, Yi-Bin , Hamadani, Mehdi , Wingard, John R. , Ueda, Masumi , Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Hill, Jason E. , King, Denise, Devine, Steven M.

Mayo Clinic

Blood | January 7, 2025 | Volume: 145 | Issue: 19 | Pages: 2138-2148

10.1182/blood.2024025154 | PMID 39775763 Get It

Abstract BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD–mutated acute myeloid leukemia (AML). A key secondary end point was to determine the impact on survival of before and/or after HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD. We conducted a post hoc analysis of the data and found that the level of MRD detected with this approach correlated remarkably with RFS and relapse risk, and that MRD detectable at any level negatively affected RFS. In the placebo arm, 42.2% of participants with detectable FLT3-ITD MRD relapsed compared with 13.4% of those without detectable MRD. We found that 14.8% of participants had multiple FLT3-ITD clones detected as MRD and had worse survival irrespective of treatment arm. Finally, we examined the kinetics of FLT3-ITD clonal relapse or eradication and found that participants on the placebo arm with detectable MRD relapsed rapidly after HCT, often within a few weeks. MRD-positive participants on the gilteritinib arm relapsed either with FLT3 wild-type clones (assessed by capillary electrophoresis), after cessation of gilteritinib with persistent MRD, or on progression of multiclonal disease. These data demonstrate the potential of FLT3-ITD MRD to guide therapy with gilteritinib for this subtype of AML. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
Neuro-Ophthalmic Literature Review
Chen, John J. , Hung, Wei-Che , Vaphiades, Michael S., Chen, John J , Mak, Andrew C. Y. , Verma, Rashmi , Zhang, Xiaojun

Mayo Clinic

Neuro-Ophthalmology | January 7, 2025 | Volume: 49 | Issue: 1 | Pages: 105-110

10.1080/01658107.2024.2431470 Get It

Increased Mortality in Kidney Transplant Recipients During the Delta/Omicron Era of the COVID‐19 Pandemic Despite Widespread Vaccination
Smith, Byron H. , Nair, S. , Mai, Martin, Khamash, Hasan , Schinstock, Carrie A. , Liang, Yun , Abdelrheem, Ahmed, Park, Walter D. , Smith, Byron , Nair, Sumi, Wadei, Hani M , Schinstock, Carrie , Park, Walter , Badley, Andrew, Stegall, Mark D , Wadei, Hani M. , Liang, Yun, Badley, Andrew D. , Stegall, Mark D.

Mayo Clinic

Clinical Transplantation | January 7, 2025 | Volume: 39 | Issue: 1 | Pages: No page available

10.1111/ctr.70071 | PMID 39777936 Get It

ABSTRACTIntroductionThe incidence of mortality late in the pandemic, particularly after widespread vaccine availability, is not well understood. Herein, we elucidate the effect of this impact of the COVID pandemic as well as risk factors for mortality during it.MethodsThe primary end point was death with a functioning graft with secondary endpoints of mortality rates in subgroups and at different time intervals during the pandemic.ResultsDespite widespread vaccination, mortality rates for kidney transplant (KTx) recipients almost doubled during the COVID‐19 era (6.40 deaths per 100 person years vs. 3.54 pre‐COVID). Mortality increased in all racial/ethnic groups but increased more in Native Americans, Hispanics, and African Americans compared to non‐Hispanic Caucasians. The highest mortality rate occurred during the Delta and Omicron time frames. In contrast to the general population, mortality was more evenly spread across age groups in KTx recipients.ConclusionsMortality rates during the COVID‐19 era were extremely high, more than doubling in some racial/ethnic groups. We conclude that the KTx population was a particularly vulnerable group during the COVID‐19 era and suggests the need for further research into the management of variants in the future.